← All trials
NCT04799236
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Apr 30, 2023
- Completion date
- Nov 30, 2023
- First posted
- Mar 16, 2021
- Last posted
- Nov 30, 2021
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundacion Nacional de DermatologiaLead sponsor
- AB Foundation for Medical ResearchCollaborator
- Centro Nacional de Enfermedades Tropicales CENETROPCollaborator
- Hospital Dermatológico de JorochitoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.